Extra-capsular growth of lymph node metastasis correlates with poor prognosis and high SOX9 expression in gastric cancer

Helena Link, Martin Angele, Miriam Schüller, Petra Ganschow, Lena Machetanz, Markus Guba, Jens Werner, Thomas Kirchner and Jens Neumann

Abstract

Background: Extra-capsular growth (ECG) describes the extension of neoplastic cells beyond the lymph node capsule. Aim of this study was to investigate the prognostic value of ECG and its association with a stem cell like phenotype indicated by expression of the transcription factor SOX9 in gastric cancer.

Methods: By histological evaluation, 199 patients with nodal positive gastric cancer or adenocarcinoma of the esophageal-gastric junction (AEG) were divided into two groups according to the presence (ECG) or absence (ICG) of extracapsular growth in at least one nodal metastasis. Of these, 194 patients were stained for SOX9 and SOX2 using immunohistochemistry. Seventeen nodal negative patients (pT3/4, pN0, pM0) served as controls.

Results: Seventy-three patients (36.7%) showed ECG. ECG was associated with lower overall survival ($p < 0.0001$), advanced pT- ($p = 0.03$) and pN- category ($p < 0.0001$) and lymphovascular invasion ($p = 0.014$). In multivariate analysis, ECG was found to be an independent prognostic factor (HR = 2.1; 95% CI 1.7–3.4; $p = 0.001$). SOX9 expression correlated significantly with ECG (96% SOX9 high in ECG patients vs. 79% SOX9 high in patients with ICG; $p = 0.002$). Controls showed significantly reduced SOX9 expression compared to nodal positive carcinomas (59% vs. 85% high SOX9 expression; $p = 0.006$). No significant correlation of ECG and SOX2 (59% SOX2 negative in ECG patients vs. 64% in patients with ICG, $p = 0.48$) could be obtained.

Conclusions: Patients with ECG exhibit poorer prognosis and ECG was found to be an independent prognostic factor. Thus, ECG turns out to be a morphological biomarker for a more aggressive phenotype in gastric cancer. This is supported by the fact that ECG correlates with the expression of SOX9, which has been described in the context of pro-oncogenic properties of tumours. However, the fact that SOX2 failed to show significant results indicate that ECG is not associated with a distinct cancer stem cell phenotype in gastric cancer.

Keywords: Gastric cancer, Lymph node metastasis, ECG, SOX9, Prognosis, Extranodal extension

Background

The extra-capsular growth (ECG) describes the extension of neoplastic cells beyond the lymph node capsule into the perinodular soft tissue. Being a prognostic factor for cancer in several organs [1, 2] including the gastrointestinal tract [3, 4], ECG has already found access to staging systems such as the squamous cell carcinoma of the vulva and the head and neck [5].

A systematic review about colorectal cancer determined ECG to be associated with poorer prognosis and a higher risk of recurrence of disease [6]. Therefore, the parameter ECG is also suggested to be included as a prognostic parameter in colorectal cancer staging systems [6]. In gastric cancer, ECG is associated with poorer 5-year survival and was also found to be an independent prognostic factor [4, 7]. ECG is associated with larger tumour size, advanced pT- and pN-category and lymphovascular and perineural invasion [4, 7].

* Correspondence: jens.neumann@med.uni-muenchen.de
† Equal contributors
1 Institute of Pathology, Faculty of Medicine, LMU Munich, Thalkirchner Straße 36, 80337, Munich, Germany
Full list of author information is available at the end of the article

© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source; provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Both SOX9 and SOX2 are members of the DNA-binding HMG domain proteins and part of the SOX-family of transcription factors. SOX2 is mainly involved in the regulation of embryonic development and in the determination of cell fate. Besides being required for the stem-cell maintenance in the central nervous system, SOX2 is known to regulate gene expression in the stomach [8]. In gastric cancer, high expression of SOX2 was found to be associated with decreased rates of lymph node metastasis and better treatment outcome [9]. SOX9 is important for sex determination as it initiates testis development. It also plays a decisive role in chondrogenesis by regulating cartilage specific gene expression [10, 11]. In the gastrointestinal tract, SOX9 is expressed in nuclei of crypt cells including Paneth and stem cells [11], playing an important role for endoderm development and homeostasis of the intestinal epithelium by interacting with the Wnt/β-catenin-signalling pathway. SOX9, together with the Wnt/β-catenin-target Slug, was found to determine the stem cell state in mammary cells by inducing differentiated luminal cells to pass through epithelial-mesenchymal transition (EMT), thus driving malignant progression an metastasis [12].

SOX9 is associated with poorer prognosis and advanced TNM category in different types of gastrointestinal cancer [13, 14]. In colorectal cancer, high SOX9 expression was found to be an independent prognostic factor [14]. Similar, in gastric cancer SOX9 overexpression is related to tumour progression and associated with lower 5-year survival, tumour invasion as well as advanced TNM category [15].

Based on these findings it was the aim of our study to analyse the prognostic value of ECG in gastric cancer as a morphological marker for a more aggressive tumour phenotype. Furthermore, we intended to analyse the association of ECG with the protein expression of the embryonic transcription factors SOX9 and SOX2 both being potential biomarkers for a stem cell like phenotype in gastric cancer.

**Methods**

**Tissue selection**
From the data bank of the Department of General, Visceral, Transplantation, Vascular and Thoracic Surgery, Medical Center of the University of Munich, 529 patients who underwent surgery for gastric cancer or adenocarcinoma of the esophageal-gastric junction (AEG) between 2002 and 2014 were selected. Cases with lymph node metastasis were extracted (n = 260) and the histological slides of 199 of the 260 nodal positive cases could be collected from the archives of the Institute of Pathology, Faculty of Medicine, LMU Munich. Clinico-pathological parameters are summarized in Table 1. The lymph node status was evaluated according to standard protocols following the national German guidelines. In brief, all lymph nodes included in the surgical specimen were dissected. Lymph nodes larger than 0.5 cm were divided in half and from each lymph node specimen two to three serial sections were prepared. In indistinct cases additional serial sections were made.

Formalin fixed and paraffin embedded (FFPE) specimens of the primary tumours of 194 of the 199 nodal positive patients were collected for immunohistochemistry. Seventeen locally advanced, nodal negative cases were excluded.

**Table 1** Correlation of the ECG/ICG-status with clinico-pathological variables at time of surgery (according to TNM Classification of Malignant Tumours 8th edition 2017). Percent-values are given in parentheses

| Characteristic | Total (%) | Capsule status | p |
|---------------|-----------|----------------|---|
|               | ECG       | ICG            |   |
| All patients  | 199 (100) | 73 (36.7)      | 126 (63.3) |
| Age (median. 66.0) years | | | |
| ≤ 66 | 100 (50.3) | 33 (16.6) | 67 (33.7) | 0.279 |
| ≥ 67 | 99 (49.7) | 40 (20.1) | 59 (29.6) |
| Gender | | | |
| Male | 128 (64.3) | 41 (20.6) | 87 (43.7) | 0.067 |
| Female | 71 (35.7) | 32 (16.1) | 39 (19.6) |
| Lauren classification | | | |
| diffuse | 69 (34.7) | 33 (16.6) | 36 (18.1) | 0.059 |
| intestinal | 108 (54.3) | 33 (16.6) | 75 (37.7) |
| mixed type | 22 (11.1) | 7 (3.5) | 15 (7.5) |
| Tumor size (UICC) | | | |
| T0 | 4 (2.0) | 1 (0.5) | 3 (1.5) | 0.032 |
| T1 | 2 (1.0) | 0 (0) | 2 (1.0) |
| T2 | 97 (48.7) | 27 (13.6) | 70 (35.2) |
| T3 | 61 (30.7) | 25 (12.6) | 36 (18.1) |
| T4 | 34 (17.1) | 19 (9.5) | 15 (7.5) |
| Tx | 1 (0.5) | 1 (0.5) | 0 (0) |
| Nodal status | | | |
| N0 | 0 (0) | 0 (0) | 0 (0) |
| N+ | 199 (100) | 73 (36.7) | 126 (63.3) |
| Distant metastasis | | | |
| M0 | 126 (63.3) | 41 (20.6) | 85 (42.7) | 0.179 |
| M1 | 58 (29.1) | 27 (13.6) | 31 (15.6) |
| Mx | 15 (7.5) | 5 (2.5) | 10 (5.0) |
| Tumor grade (WHO) | | | |
| G1 | 2 (1.0) | 1 (0.5) | 1 (0.5) | 0.207 |
| G2 | 31 (15.6) | 7 (3.5) | 24 (12.1) |
| G3 | 162 (81.4) | 63 (31.7) | 99 (49.7) |
| Gx | 4 (2.0) | 2 (1.0) | 2 (1.0) |

Significant results are indicated by bold numbers.
patients without distant metastasis (pT3/4, pN0, pM0) served as controls (Fig. 1). The histological slides of all lymph node positive cases ($n = 199$) were evaluated by two independent observers (JN and HL) according to the presence (ECG) or absence (ICG) of extracapsular growth in at least one nodal metastasis (Fig. 2a-d).

**Immunohistochemistry**

Immunohistochemical stainings were performed using 5 μm serial tissue sections of representative FFPE tumour samples. For SOX9 specific immunohistochemistry first a heat-induced epitope retrieval was done applying ProTaqa IV Anitgen-Enhancer (Quartett, Germany) before adding primary SOX9 specific rabbit monoclonal antibody (1:100, SOX9 clone D8G8H, Cell Signalling Technology, Danvers, MA) for 60 min at room temperature. Thereafter, a development step was introduced by adding detection-system (Vectastain ABC-Kit Elite Universal, Biozol, Germany) and subsequently substrate-chromogen containing DAB+ system (DAKO, Germany) according to the respective manufacturer’s protocols.

For SOX2 specific immunohistochemistry heat-induced epitope retrieval was performed applying Epitope Retrieval Solution (Novocastra, Germany) followed by adding primary SOX2 specific rabbit monoclonal antibody (1:50, SOX2 clone D6D9, Cell Signalling Technology, Danvers, MA) for 60 min at room temperature. The development step was made by adding the detection-system (ImmPRESS Reagent Kit Anti-RABBIT Ig, Vector, Germany) and substrate-chromogen containing DAB+ system (DAKO, Germany).

Finally, for both markers slides were counterstained using Hematoxylin (Vector Laboratories, Burlingame, CA). To control for unspecific binding of antibodies, isotype controls were included (data not shown).

**Scoring of immunohistochemistry**

Immunohistochemistry both for SOX9 and SOX2 were evaluated independently by two observers (JN and HL). Nuclear staining was reported for both, percentage and intensity of stained nuclei throughout the tumour. Intensity values were categorized as follows: no staining – 0, weak – 1, moderate – 2 and strong – 3. The staining of SOX9 was evaluated as follows: when less than 30% of tumour cells were stained and/or the intensity was missing (0) or weak (1), immunostaining was reported to be negative (Fig. 3a and b). When less than 10% of tumour cells were stained for SOX2 and/or the intensity was missing (0) or weak (1), immunostaining was reported to be negative (Fig. 3c and d). Discrepant cases were discussed and a consensus was reached.
Fig. 2 Overview of lymph-node metastasis of gastric cancer with ECG (a) and ICG (b). The frames indicate areas shown with higher magnification in c and d (200-fold, hematoxylin and eosin stain), respectively.

Fig. 3 Immunohistochemical staining of SOX9 and SOX2 in gastric adenocarcinoma (200-fold magnification). In a adenocarcinoma with high and in b with low immunohistochemical expression of SOX9 are shown. Adenocarcinoma with positive and negative SOX2 expression is shown in c and in d, respectively.
Statistics
All statistics were calculated using SPSS v.17.0 (SPSS Inc.). Significance of correlations of the immunohistochemical analyses was calculated using the $\chi^2$-test. Survival analysis was performed using Kaplan-Meier-test and multivariate Cox-regression. For all tests a $p$-value of $p < 0.05$ was considered statistically significant.

Results
The average number of the lymph nodes being observed was 24.4 (min. 3, max. 85). Seventy-three patients (36.7%) showed ECG (Fig. 4a). The mean number of lymph nodes with ECG was 2.6 (min. 1, max. 12). Presence of ECG was associated with significantly lower overall survival ($p < 0.0001$; Fig. 4b). Patients with ECG had a median survival of 21.2 months (95% confidence interval (CI) 16.69–20.74; standard deviation (SD) 2.31) whereas patients without ECG had a median survival of 37.07 months (95% CI 30.28–43.85; SD 3.46). In univariate analysis, cox-regression detected a hazard ratio (HR) of 2.4 (95% CI 1.7–3.4; $p < 0.0001$).

Regarding the subgroup of stage UICC II patients ($n = 76$), ECG was also associated with significantly lower overall survival ($p = 0.001$). The median survival of stage II patients with ECG ($n = 16$) was 21.0 months (95% CI 11.3–30.6; SD 5.0) whereas stage II patients with ICG ($n = 60$) had a median survival of 50.7 months (95% CI 39.0–62.4; SD 6.0). In univariate cox-regression, the HR was 2.9 (95% CI 1.5–5.6; $p = 0.001$). In multivariate analysis, ECG was found to be a prognostic factor (HR = 2.1; 95% CI 1.7–3.4; $p = 0.001$), independent from T- and N-category, UICC-stage and lymphangiosis carcinomatosa.

Presence of ECG was associated with advanced pT-category ($p = 0.03$; Fig. 5a) and pN-category ($p < 0.0001$; Fig. 5b) but not with the presence of distant metastases (pM category, $p = 0.067$; Fig. 5c). In category pT2 ($n = 97$), 28% showed an ECG, whereas in category pT3 ($n = 61$) it was 41% and in pT4 ($n = 34$) even 56% ($p = 0.03$). The association with pN-category was highly significant ($p < 0.0001$); the percentage of cases with ECG doubled from category pN1 to pN2 and tripled from pN1 to pN3 (pN1: $n = 89$, ECG 19%; pN2: $n = 59$, ECG = 41%; pN3: $n = 51$, ECG = 63%).

ECG was further associated with lymphovascular invasion. Forty-two percent of cases with lymphangiosis carcinomatosa (L1, $n = 143$) showed ECG whereas among patients without lymphangiosis carcinomatosa (L0, $n = 56$) it was only 23% (Fig. 5d). The majority of nodal positive cases were classified as SOX9-high positive ($n = 165$, 85%; Fig. 3a). Twenty-nine patients showed low or missing SOX9 expression and were classified as negative ($n = 29$, 15%; Fig. 3b). Ten of seventeen (59%) control cases showed high positive SOX9 expression. In contrast to these results, the majority of nodal positive cases were classified as SOX2-negative ($n = 120$, 62%, Fig. 3d). 74 patients showed positive SOX2 expression ($n = 74$, 38%, Fig. 3c). Ten of seventeen (59%) control cases showed negative SOX2 expression.

SOX9 expression correlated significantly with ECG (96% high positive SOX9 expression in ECG patients vs. 79% high positive SOX9 expression in ICG patients; $p = 0.002$; Fig. 6a). The controls showed a significantly lower rate of high positive SOX9 expression compared to the nodal positive carcinomas (nodal positive: 85% high positive SOX9 expression; control:...
Correlations of SOX9 expression with clinic-pathological parameters are shown in Table 2. There was no significant correlation between SOX2 expression and ECG (59% negative SOX2 expression in ECG patients vs. 64% negative SOX2 expression in ICG patients, \( p = 0.48 \), Fig. 6c). Neither SOX9 nor SOX2 expression were associated with poorer prognosis (data not shown).

**Discussion**

Extracapsular growth has become an important part of oncological studies in the last years. The association of ECG and poorer prognosis, both in gastric cancer [4] and in gastrointestinal malignancies in general [3], turns the parameter ECG into an interesting target for recent studies regarding tumours of the gastrointestinal tract [5, 16, 17]. Its association with histomorphological parameters such as TNM-category, lymphovascular invasion and tumour grading [6, 7] implies ECG to be a morphological marker for a more aggressive biological phenotype of gastrointestinal cancer. Recently, extranodal extension already became a part of the lymph node category of head and neck cancer staging systems [18, 19]. Therefore, there is huge evidence that ECG should find access to tumour staging classifications of gastrointestinal malignancies in addition to the established staging systems TNM and UICC.

Our results are in concordance with previously published data. In this study, we could confirm ECG to be associated with poorer prognosis and multivariate analysis identified ECG to be an independent prognostic factor. In addition, the yet known correlation of ECG and histomorphological parameters could be retraced in this study as ECG was significantly associated with higher pT- and pN- categories and the presence of lymphovascular invasion. Thus, from the accordance of our results with recently published data it may be concluded that the results of this study are representative for gastric cancer patients in general.

Since ECG seems to be a morphological marker for a more aggressive tumour phenotype there may be an association of ECG with other markers for aggressive growth. Of interest, we could not obtain a correlation of ECG and Lauren classification, although diffuse-type carcinomas are known to grow aggressively and to be associated with bad prognosis [20]. Thus, it could be concluded that ECG is more likely associated with intrinsic factors such as pro-oncogenic properties of tumour cells. In this study, we analysed two different markers associated with stem cell features of tumour cells in the literature. As our data show a significant correlation between ECG and the marker SOX9, it could be assumed from our data that ECG may be associated with stemness properties in gastric cancer. SOX9 turned out to be an important stem
cell marker for gastrointestinal and other malignancies. In mammary cell carcinoma, SOX9 is known to be partly responsible for the determination of the stem cell state by inducing epithelial mesenchymal transition (EMT) [12], which is also known to play a decisive role in the genesis of gastrointestinal tumours [21, 22]. Furthermore, high SOX9 expression is associated with advanced TNM category, poorer prognosis and tumour progression, both in gastric cancer and other types of gastrointestinal cancer [13–15, 23]. The deletion of SOX9 results in an increased epithelial proliferation and intestinal hyperplasia [10, 24]. Nevertheless, it remains controversial, whether SOX9 is a suitable stem cell marker in gastric cancer. In our collection of gastric cancer patients we could demonstrate a significant association of ECG and SOX9 but no correlation between ECG and SOX2, which is an established stem cell marker in gastric cancer [25]. Thus, we could not proof a correlation of EGC with a distinct stem cell phenotype. However, it could be concluded from our data that SOX9 acts as a pro-oncogene in gastric cancer and plays an important role in gastric cancer progression and formation of ECG in lymph node metastasis.

Fig. 6 Correlation of SOX9 and SOX2 expression with ECG and ICG (a, c) and with the presence or absence of lymph-node metastasis (b, d)
In this study, the expression of SOX9 was neither associated with survival nor with pT- or pM-category which is mainly due to the fact that our data primarily includes nodal positive patients and is therefore biased. However, our data did show a significant association of high SOX9 expression and nodal status and the presence of ECG. From the fact that cases with extracapsular growth show higher SOX9 expression it can be concluded that ECG is a promising biomarker for a more aggressive gastric cancer phenotype. Further studies, especially on molecular levels need to be done in order to understand the functional and biological aspects of ECG and the intrinsic significance and exact mechanism of pro-oncogenes such as SOX9.

**Conclusions**

In summary, our data confirm that ECG is an independent prognostic factor and a potential morphological biomarker for a more aggressive phenotype in gastric cancer.

### Table 2

| Characteristic | Total (%) | SOX9 high positive | SOX9 negative | p |
|---------------|-----------|---------------------|---------------|---|
| All patients  | 211 (100) | 175 (82.9)          | 36 (17.1)     |   |
| Age (median, 66.5) years | | | | |
| ≤ 66          | 104 (49.3) | 81 (38.4)           | 23 (10.9)     | 0.054 |
| ≥ 67          | 107 (50.7) | 94 (44.5)           | 13 (6.2)      |   |
| Gender        |           |                     |               |   |
| Male          | 135 (64.0) | 111 (52.6)          | 24 (11.4)     | 0.712 |
| Female        | 76 (36.0)  | 64 (30.3)           | 12 (5.7)      |   |
| Lauren classification | | | | |
| diffuse       | 74 (35.1)  | 58 (27.5)           | 16 (7.6)      | 0.290 |
| intestinal    | 113 (53.6) | 98 (46.4)           | 15 (7.1)      |   |
| mixed type    | 24 (11.4)  | 19 (9.0)            | 5 (2.4)       |   |
| Tumor size (UICC) | | | | |
| T0            | 4 (1.9)    | 2 (0.9)             | 2 (0.9)       | 0.286 |
| T1            | 2 (0.9)    | 2 (0.9)             | 0 (0)         |   |
| T2            | 96 (45.5)  | 81 (38.4)           | 15 (7.1)      |   |
| T3            | 73 (34.6)  | 58 (27.5)           | 15 (7.1)      |   |
| T4            | 35 (16.6)  | 31 (14.7)           | 4 (1.9)       |   |
| Tx            | 1 (0.5)    | 1 (0.5)             | 0 (0)         |   |
| Nodal status  |           |                     |               | 0.006 |
| N0            | 17 (8.1)   | 10 (4.7)            | 7 (3.3)       |   |
| N+            | 194 (91.9) | 165 (78.2)          | 29 (13.7)     |   |
| Capsule status of N+ cases | | | | |
| extra-capsular growth (ECG) | 70 (33.2) | 67 (31.8) | 3 (1.4) | 0.0003 |
| intra-capsular growth (ICG) | 124 (58.8) | 98 (46.4) | 26 (12.3) |   |
| Distant metastasis | | | | |
| M0            | 137 (64.9) | 111 (52.6)          | 26 (12.3)     | 0.565 |
| M1            | 58 (27.5)  | 49 (23.2)           | 9 (4.3)       |   |
| Mx            | 16 (7.6)   | 15 (7.1)            | 1 (0.5)       |   |
| Tumor grade (WHO) | | | | |
| G1            | 2 (0.9)    | 2 (0.9)             | 0 (0)         | 0.816 |
| G2            | 31 (14.7)  | 26 (12.3)           | 5 (2.4)       |   |
| G3            | 173 (82.0) | 144 (68.2)          | 29 (13.7)     |   |
| Gx            | 5 (2.4)    | 3 (1.4)             | 2 (0.9)       |   |

Significant results are indicated by bold numbers.
cancer. This is supported by the fact that ECG correlates with the expression of SOX9 indicating that this biomarker probably plays an important role in the pathogenesis of gastric cancer and ECG formation. Thus, it could be concluded from our data that in gastric cancer ECG, similar to tumour of the vulva and the head and neck region, should be integrated in established cancer staging systems such as TNM and UICC.

Abbreviations
AEG: Adenocarcinoma of the esophageal-gastric junction; Cl: Confidence interval; ECG: Extra-capsular growth; EMT: Epithelial-mesenchymal transition; FFPE: Formalin fixed and paraffin embedded; HR: Hazard ratio; ICG: Intracapsular growth; SD: Standard deviation

Acknowledgements
We thank A. Heier, I. Redich and A. Sendelhofert for excellent technical assistance.

Funding
No specific funding was received for this study.

Availability of data and materials
The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
HL Participated in the coordination of the study, the selection of the case collection, evaluated the HE slides and the SOX9 and SOX2 immunohistochemistry, performed the statistical analysis and drafted the manuscript. MA Is one of the two principal investigators and conceived of the study, participated in the design and coordination of the study, provided funding and helped to draft the manuscript. MS Participated in the design and selection of the case collection. PG Participated in the design and provided clinical data. LM Developed the clinical database and provided clinical data. MG Participated in the design of the study and interpretation of data. JW Participated in the design of the study and provided funding. TK Conceived of the study, provided funding and helped to draft the manuscript. JN Is one of the two principal investigators and conceived of the study, participated in the design and coordination of the study, provided funding, evaluated the HE slides and the SOX9 and SOX2 immunohistochemistry and helped to draft the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate
This study was carried out according to the recommendations of the ethics committee of the Medical Faculty of the Ludwig-Maximilians-University Munich, Germany. The current study has been performed in a retrospective manner in a cohort of patients diagnosed and treated according to national guidelines. In addition, the data sets as well as the specimens were irreversibly anonymized prior to inclusion in the study. Hence, under the circumstances aforementioned, neither a written consent nor a project specific approval by the ethic committee was necessary. The study was performed according to the standards set in the Declaration of Helsinki 1975. All researchers were blinded from patient data during experimental analysis.

Competing interests
J. Neumann is Associate Editor of BMC Cancer and thus member of the editorial board. All other authors have no potential competing interests and declare full transparency.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Institute of Pathology, Faculty of Medicine, LMU Munich, Thalkirchner Straße 36, 80337, Munich, Germany. 2Department of General, Visceral, Transplantation, Vascular and Thoracic Surgery, Medical Center of the University of Munich, Munich, Germany. 3German Cancer Consortium (DKTK), 69120 Heidelberg, Germany. 4German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.

Received: 26 October 2017 Accepted: 19 April 2018
Published online: 27 April 2018

References
1. Ahn TS, Kim HS, Jeong CW, Kwak C, Kim HH, Ku JH. Extracapsular extension of pelvic lymph node metastasis in bladder Cancer: a systematic review and meta-analysis. Ann Surg Oncol. 2015;22(11):3745–50.
2. Griebeling TL, Ozkutlu D, See WA, Cohen MB. Prognostic implications of extracapsular extension of lymph node metastases in prostate cancer. Mod Pathol. 1997;10(8):804–9.
3. Wind J, Lagarde SM, Ten Kate FJ, Ubbink DT, Bemelman WA, van Lanschot JJ. A systematic review on the significance of extracapsular lymph node involvement in gastrointestinal malignancies. Eur J Surg Oncol. 2007;33(5):401–8.
4. Alkus H, Holscher AH, Grass G, Hartmann E, Schulte C, Drebber U, et al. Extracapsular lymph node spread: a new prognostic factor in gastric cancer. Cancer. 2010;116(2):309–15.
5. Luchini C, Nottegar A, Solmi M, S ergi G, Manzato E, Capelli P, et al. Prognostic implications of extranodal extension in node-positive squamous cell carcinoma of the vulva: a systematic review and meta-analysis. Surg Oncol. 2016;25(1):60–5.
6. Veronese N, Nottegar A, Pea A, Solmi M, Stubbs B, Capelli P, et al. Prognostic impact and implications of extracapsular lymph node involvement in colorectal cancer: a systematic review with meta-analysis. Ann Oncol. 2016;27(1):42–8.
7. Lee IS, Park YS, Ryu MH, Song MJ, Yook JH, Oh ST, et al. Impact of extranodal extension on prognosis in lymph node-positive gastric cancer. Br J Surg. 2014;101(12):1576–84.
8. Carrasco-Garcia E, Santos JC, Garcia I, Brianti M, Garcia-Puga M, Pedrazzoli J Jr, Mathieu A, Ribeiro ML. Paradoxical role of SOX2 in gastric cancer. Am J Cancer Res. 2016;6(4):701–13. eCollection 2016. Review. PMID: 27186426.
9. Chen Y, Huang Y, Zhu L, Chen M, Huang Y, Zhang J, et al. SOX2 inhibits metastasis in gastric cancer. J Cancer Res Clin Oncol. 2016;142(6):1221–30.
10. Kormish JD, Sinner D, Zorn AM. Interactions between SOX factors and Wnt/beta-catenin signaling in development and disease. Dev Dyn. 2010; 239(1):56–68.
11. Jo A, Denduluri S, Zhang B, Wang Z, Yin L, Yan Z, et al. The versatile functions of Sox9 in development, stem cells, and human diseases. Genes Dev. 2014;28(2):149–61.
12. Guo W, Keckesova Z, Donaher JL, Tischler V, Reinhardt F, et al. Slug and Sox9 cooperatively determine the mammary stem cell state. Cell. 2012;148(5):1015–28.
13. Hong Y, Chen W, Du X, Ning H, Chen H, Shi R, et al. Upregulation of sex-determining region Y-box 9 (SOX9) promotes cell proliferation and tumorigenicity in esophageal squamous cell carcinoma. Oncotarget. 2015; 6(31):31241–54.
14. Lu B, Fang Y, Xu J, Wang L, Xu F, Xu E, et al. Analysis of SOX9 expression in colorectal cancer. Am J Pathol. 2008;173(6):1897–904.
15. Zhou CJ, Guo Q, Zhu HK, Zhang QH, Pan CR, Xu WH, et al. Elevated expression of SOX9 is related with the progression of gastric carcinoma. Diagn Cytopathol. 2011;39(2):105–9.
16. Kim CW, Kim J, Yeom SS, Lee JL, Yoon YS, Park J, et al. Extranodal extension status is a powerful prognostic factor in stage III colorectal cancer. Oncotarget. 2017;8(37):56139–40.
17. Veronese N, Fassan M, Wood LD, Stubbs B, Solmi M, Capelli P, et al. Extranodal extension of nodal metastases is a poor prognostic Indicator in gastric Cancer. A systematic review and meta-analysis. J Gastrointest Surg. 2016;20(10):1692–8.
18. Lydiatt WM, Patel SG, O’Sullivan B, Brandwein MS, Ridge JA, Migliacci JC, et al. Head and neck cancers-major changes in the American joint committee on cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(2):122–37.
19. Link H, Schüller M, Ganschow P, Bazhin A, Guba M, Werner J, et al. Extra-capsular growth of lymph node metastasis correlates with poor prognosis and high SOX9 expression in gastric cancer [abstract]. Pathologe. 2017;38(Suppl 1)

20. Yu CC, Levison DA, Dunn JA, Ward LC, Demonakou M, Allum WH, et al. Pathological prognostic factors in the second British stomach Cancer group trial of adjuvant therapy in resectable gastric cancer. Br J Cancer. 1995;71(5):1106–10.

21. Katoh M. Epithelial-mesenchymal transition in gastric cancer (review). Int J Oncol. 2005;27(6):1677–83.

22. Wu C, Zhuang Y, Jang S, Liu S, Zhou J, Wu J, et al. Interaction between Wnt/beta-catenin pathway and microRNAs regulates epithelial-mesenchymal transition in gastric cancer (review). Int J Oncol. 2016;48(6):2236–46.

23. Shao CM, Shao QS, Yao HB, Zhao ZK, Xu J, Zhao ZS, et al. Association of SOX9 expression and prognosis in patients with gastric cancer. Zhonghua Wei Chang Wai Ke Za Zhi. 2012;15(7):736–9.

24. Bastide P, Darido C, Pannequin J, Kist R, Robine S, Marty-Double C, et al. Sox9 regulates cell proliferation and is required for Paneth cell differentiation in the intestinal epithelium. J Cell Biol. 2007;178(4):635–48.

25. Hutz K, Mejias-Luque R, Farsakova K, Ogris M, Krebs S, Anton M, et al. The stem cell factor SOX2 regulates the tumorigenic potential in human gastric cancer cells. Carcinogenesis. 2014;35(4):942–50.